Back to top
more

Provention Bio, Inc. (PRVB)

(Delayed Data from NSDQ)

$3.98 USD

3.98
53,291

+0.18 (4.74%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.92 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong

by Zacks Equity Research

Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

by Zacks Equity Research

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sanofi (SNY) Surpass Estimates This Earnings Season?

by Zacks Equity Research

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent.

Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi

by Zacks Equity Research

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

Ethan Feller headshot

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

by Ethan Feller

Last week ended on a hectic note...

Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)

by Zacks Equity Research

Provention Bio, Inc. (PRVB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

by Zacks Equity Research

Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.

Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 26.09% and 13.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug

by Zacks Equity Research

Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.

Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?

by Zacks Equity Research

Provention Bio, Inc. (PRVB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Provention Bio, Inc. (PRVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 187.1% in Provention Bio, Inc. (PRVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 8.51% and -81.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 9.80% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Aditi Saraogi headshot

Implied Volatility Surging for Provention Bio (PRVB) Stock Options

by Aditi Saraogi

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

Aditi Saraogi headshot

Implied Volatility Surging for Provention Bio (PRVB) Stock Options

by Aditi Saraogi

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Provention Bio (PRVB) Stock?

by Zacks Equity Research

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.